An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis (Q45270105)

11 December 2017

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis (English)

1 reference

11 December 2017

1 reference

Rosanne M Crooke

1

1 reference

11 December 2017

Mark J Graham

2

1 reference

11 December 2017

Kristina M Lemonidis

3

1 reference

11 December 2017

Charles P Whipple

4

1 reference

11 December 2017

Seonjoon Koo

5

1 reference

11 December 2017

Ranjan J Perera

6

1 reference

11 December 2017

16 February 2005

1 reference

Journal of Lipid Research

11 December 2017

1 reference

11 December 2017

46

1 reference

11 December 2017

5

1 reference

11 December 2017

872-884

1 reference

2000 George Lyman Duff Memorial Lecture: atherosclerosis is a liver disease of the heart

11 December 2017

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Subendothelial retention of atherogenic lipoproteins in early atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Very-low-density lipoprotein assembly and secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Familial combined hyperlipidemia plasma stimulates protein secretion by HepG2 cells: identification of fibronectin in the differential secretion proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Apolipoprotein B mRNA editing and the reduction in synthesis and secretion of the atherogenic risk factor, apolipoprotein B100 can be effectively targeted through TAT-mediated protein transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Intestinal lipoprotein assembly in apobec-1-/- mice reveals subtle alterations in triglyceride secretion coupled with a shift to larger lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

A genetic model for absent chylomicron formation: mice producing apolipoprotein B in the liver, but not in the intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

The myotoxicity of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M400492-JLR200

10.1194/JLR.M400492-JLR200

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference